Biliverdin reductase A is a major determinant of protective NRF2 signaling

Journal:

Proceedings of the National Academy of Sciences of the United States of America

Published:

2025-09-30

DOI:

10.1073/pnas.2513120122

Affiliations:

21

Authors:

22

Go to article

Institutions	Authors	Share
Johns Hopkins Medicine (JHM), JHU, United States of America (USA)	9.750000	0.44
Hollings Cancer Center, MUSC, United States of America (USA)	4.000000	0.18
Medical University of South Carolina (MUSC), United States of America (USA)	2.000000	0.09
NIH National Library of Medicine (NLM), United States of America (USA)	2.000000	0.09
Case Western Reserve University (CWRU), United States of America (USA)	1.166667	0.05
Sapienza University of Rome, Italy	1.000000	0.05
Baylor College of Medicine (BCM), United States of America (USA)	0.666667	0.03
University Hospitals Cleveland Medical Center, CWRU, United States of America (USA)	0.666667	0.03
Texas Children's Hospital, BCM, United States of America (USA)	0.333333	0.02
Lieber Institute for Brain Development (LIBD), United States of America (USA)	0.250000	0.01
Louis Stokes Cleveland VA Medical Center (VAMC), United States of America (USA)	0.166667	0.01

Interested in Oncology and Carcinogenesis?